Biomarker & Intervention Discovery

Vitiligo

This page lists 10 druggable gene targets, 45 approved or trial-tested drug candidates and 15 recent clinical trials for Vitiligo, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs2.23MWHO GHE 2021 · all ages
Global DALYs41.44MWHO GHE 2021 · worldwide
US mortality6,479 deaths/yrWHO GHE 2021
Global mortality92.1K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionSpontaneous complete repigmentation extremely rare (<1%); partial spontaneous repigmentation possible in small…
Best-intervention remissionRuxolitinib cream (Opzelura): 29.9% F-VASI75 (75% facial repigmentation) at 24 weeks vs 7.5% vehicle; NB-UVB…
Gap sizeLarge — first topical treatment only approved 2022; NB-UVB is effective but access to specialised units is limited
Primary barrieraccess
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous complete repigmentation extremely rare (<1%); partial spontaneous repigmentation possible in small lesions; progressive without treatment in most patients
Best-intervention remission
Ruxolitinib cream (Opzelura): 29.9% F-VASI75 (75% facial repigmentation) at 24 weeks vs 7.5% vehicle; NB-UVB phototherapy: 75%+ repigmentation in 30-40% of patients at 12 months; excimer laser for localised vitiligo: 75%+ repigmentation in 50-70%; combination ruxolitinib + NB-UVB: superior to either alone
Gap size
Large — first topical treatment only approved 2022; NB-UVB is effective but access to specialised units is limited
Primary barrier
access
Prior to ruxolitinib cream (2022), there was no FDA-approved pharmacotherapy for vitiligo; NB-UVB is effective but requires 2-3x/week sessions for months and is only available in dermatology/phototherapy units; cosmetic dismissal of vitiligo as 'not a medical disease' has delayed research and treatment access

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CXCL10 17CXCR3 190IFNG 31IL15 38IL2RB 14JAK1 233JAK2 307MC1R 139TYK2 223TYR 162
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHORIOGONADOTROPIN ALFA ? unclear Mechanistic
TESTOSTERONE ? unclear Mechanistic
ATROPINE ? unclear Mechanistic
METHYLPREDNISOLONE ? unclear Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ELDELUMAB ↓ inhibits Mechanistic
OXALIPLATIN ? unclear Mechanistic
GM-CSF ? unclear Mechanistic
RITONAVIR ? unclear Mechanistic
ZIDOVUDINE ? unclear Mechanistic
ANTIBIOTIC ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
STAVUDINE ? unclear Mechanistic
NI-0801 ↓ inhibits Mechanistic
IROPLACT ? unclear Mechanistic
CHEMBL5081237 ↓ inhibits Mechanistic 19540.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CCL11 ↓ inhibits Mechanistic
HYPOGLAUCIN A ↓ inhibits Mechanistic
CCL7 ↓ inhibits Mechanistic
KALLSTROEMIN D ↓ inhibits Mechanistic
CXCL10 ↑ activates Mechanistic
DURAMYCIN ↓ inhibits Mechanistic
CXCL12&ALPHA; ↑ activates Mechanistic
ACT-777991 ↓ inhibits Mechanistic
CCL5 ↑ activates Mechanistic
CCL13 ↑ activates Mechanistic
CCL19 ↑ activates Mechanistic
AMG487 ↓ inhibits Mechanistic
[125I]CXCL11 (HUMAN) ↑ activates Mechanistic
NBI-74330 ↓ inhibits Mechanistic
ACT-660602 ↓ inhibits Mechanistic
CXCL11 ↑ activates Mechanistic
CCL20 ↑ activates Mechanistic
[125I]CXCL10 (HUMAN) ↑ activates Mechanistic
CXCL9 ↑ activates Mechanistic
DIOSCIN ↓ inhibits Mechanistic
CHEMBL196248 ↓ inhibits Mechanistic 15000.0 nM (IC50)
CHEMBL383346 ↓ inhibits Mechanistic 3300.0 nM (IC50)
CHEMBL194494 ↓ inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL196885 ↓ inhibits Mechanistic 930.0 nM (IC50)
CHEMBL193448 ↓ inhibits Mechanistic 3100.0 nM (IC50)
CHEMBL370482 ↓ inhibits Mechanistic 10000.0 nM (IC50)
CHEMBL197368 ↓ inhibits Mechanistic 5800.0 nM (IC50)
CHEMBL197818 ↓ inhibits Mechanistic 70.0 nM (IC50)
CHEMBL370167 ↓ inhibits Mechanistic 13000.0 nM (IC50)
CHEMBL200891 ↓ inhibits Mechanistic 9800.0 nM (IC50)
CHEMBL382000 ↓ inhibits Mechanistic 890.0 nM (IC50)
CHEMBL372403 ↓ inhibits Mechanistic 800.0 nM (IC50)
CHEMBL382938 ↓ inhibits Mechanistic 50.0 nM (IC50)
CHEMBL199406 ↓ inhibits Mechanistic 60.0 nM (IC50)
CHEMBL199301 ↓ inhibits Mechanistic 60.0 nM (IC50)
CHEMBL373008 ↓ inhibits Mechanistic 2150.0 nM (IC50)
CHEMBL371298 ↓ inhibits Mechanistic 2160.0 nM (IC50)
CHEMBL372528 ↓ inhibits Mechanistic 250.0 nM (IC50)
CHEMBL199408 ↓ inhibits Mechanistic 1250.0 nM (IC50)
CHEMBL382502 ↓ inhibits Mechanistic 420.0 nM (IC50)

Showing top 40 of 190 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
GANCICLOVIR ? unclear Mechanistic
EMAPALUMAB ↓ inhibits Mechanistic
PEFLOXACIN ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
AMITRIPTYLINE HYDROCHLORIDE ? unclear Mechanistic
MELPHALAN ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
EDRECOLOMAB ? unclear Mechanistic
METHYLPREDNISOLONE ? unclear Mechanistic
DOXIFLURIDINE ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
URSODIOL ? unclear Mechanistic
PREDNISONE ? unclear Mechanistic
BLEOMYCIN ? unclear Mechanistic
AMIKACIN ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
FONTOLIZUMAB ↓ inhibits Mechanistic
AMG-811 ↓ inhibits Mechanistic
THEOPHYLLINE ? unclear Mechanistic
PENICILLIN G POTASSIUM ? unclear Mechanistic
TRASTUZUMAB ? unclear Mechanistic
FUMARIC ACID ? unclear Mechanistic
SURAMIN ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ? unclear Mechanistic
THERAPEUTIC MELATONIN ? unclear Mechanistic
THERAPEUTIC AUTOLOGOUS LYMPHOCYTES ? unclear Mechanistic
THROMBIN ALFA ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
RECOMBINANT INTERLEUKIN-1-BETA ? unclear Mechanistic
CHEMBL3288259 ↓ inhibits Mechanistic 10000.0 nM (Kd)
CHEMBL3288260 ↓ inhibits Mechanistic 7000.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
IMMUNOADJUVANT ? unclear Mechanistic
RECOMBINANT CD40-LIGAND ? unclear Mechanistic
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
CYCLOSPORINE ? unclear Mechanistic
ORDESEKIMAB ? unclear Mechanistic
MEGESTROL ACETATE ? unclear Mechanistic
MYCOPHENOLATE MOFETIL ? unclear Mechanistic
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic
LEVODOPA ? unclear Mechanistic
SIROLIMUS ? unclear Mechanistic
LYMPHOKINE-ACTIVATED KILLER CELLS ? unclear Mechanistic
CHEMBL4102828 ↓ inhibits Mechanistic 48400.0 nM (Kd)
CHEMBL4103753 ↓ inhibits Mechanistic 19100.0 nM (Kd)
CHEMBL4085144 ↓ inhibits Mechanistic 11600.0 nM (Kd)
CHEMBL4101575 ↓ inhibits Mechanistic 24100.0 nM (Kd)
CHEMBL4066271 ↓ inhibits Mechanistic 19600.0 nM (Kd)
CHEMBL4093847 ↓ inhibits Mechanistic 21200.0 nM (Kd)
CHEMBL4087773 ↓ inhibits Mechanistic 42400.0 nM (Kd)
CHEMBL4088685 ↓ inhibits Mechanistic 26000.0 nM (Kd)
CHEMBL4096400 ↓ inhibits Mechanistic 19000.0 nM (Kd)
CHEMBL4069144 ↓ inhibits Mechanistic 20900.0 nM (Kd)
CHEMBL4070160 ↓ inhibits Mechanistic 25000.0 nM (Kd)
CHEMBL4101389 ↓ inhibits Mechanistic 21800.0 nM (Kd)
CHEMBL4066088 ↓ inhibits Mechanistic 78000.0 nM (Kd)
CHEMBL4067098 ↓ inhibits Mechanistic 16000.0 nM (Kd)
CHEMBL4864820 ↓ inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL4878149 ↓ inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4848978 ↓ inhibits Mechanistic 20000.0 nM (IC50)
CHEMBL4875914 ↓ inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4868024 ↓ inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4851186 ↓ inhibits Mechanistic 710.0 nM (IC50)
CHEMBL4846844 ↓ inhibits Mechanistic 280.0 nM (IC50)
CHEMBL4864898 ↓ inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL4847472 ↓ inhibits Mechanistic 14900.0 nM (IC50)
CHEMBL4861648 ↓ inhibits Mechanistic 20000.0 nM (IC50)
CHEMBL4857666 ↓ inhibits Mechanistic 50.0 nM (IC50)
CHEMBL4852416 ↓ inhibits Mechanistic 3900.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BEMPEGALDESLEUKIN ? unclear Mechanistic
DENILEUKIN DIFTITOX ~ modulates Mechanistic
MIK-BETA-1 ↓ inhibits Mechanistic
BASILIXIMAB ↓ inhibits Mechanistic
ALDESLEUKIN ? unclear Mechanistic
HUMIK-BETA-1 ↓ inhibits Mechanistic
RECOMBINANT HUMAN INTERLEUKIN-15 ↑ activates Mechanistic
DACLIZUMAB ↓ inhibits Mechanistic
LEUKOCYTE INTERLEUKIN ? unclear Mechanistic
HUMAN INTERLEUKIN-2 ? unclear Mechanistic
SIMLUKAFUSP ALFA ~ modulates Mechanistic
RECOMBINANT INTERLEUKIN-2 ? unclear Mechanistic
PEGENZILEUKIN ↑ activates Mechanistic
NOGAPENDEKIN ALFA INBAKICEPT ↑ activates Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TRICETAMIDE ↓ inhibits Mechanistic
NEZULCITINIB ↓ inhibits Mechanistic
IVARMACITINIB ↓ inhibits Mechanistic
OCLACITINIB ↓ inhibits Mechanistic
MOMELOTINIB ↓ inhibits Mechanistic 11.0 nM (IC50)
DECERNOTINIB ↓ inhibits Mechanistic
GOLIDOCITINIB ↓ inhibits Mechanistic
UPADACITINIB ↓ inhibits Mechanistic
LEPZACITINIB ↓ inhibits Mechanistic
BREPOCITINIB ↓ inhibits Mechanistic
COMPOUND 30 [PMID: 37057760] ↓ inhibits Mechanistic
WXFL10203614 ↓ inhibits Mechanistic
LIRUCITINIB ↓ inhibits Mechanistic
VEXICITINIB ↓ inhibits Mechanistic
ILGINATINIB ↓ inhibits Mechanistic
COMPOUND 5E [PMID: 28580438] ↓ inhibits Mechanistic
COMPOUND 25AP [PMID: 37796543] ↓ inhibits Mechanistic
ZEMPROCITINIB ↓ inhibits Mechanistic
PEMBROLIZUMAB ? unclear Mechanistic
AZD1480 ↓ inhibits Mechanistic
CERDULATINIB ↓ inhibits Mechanistic
LONDAMOCITINIB ↓ inhibits Mechanistic
JAK INHIBITOR 20A ↓ inhibits Mechanistic
FILGOTINIB ↓ inhibits Mechanistic
GUSACITINIB ↓ inhibits Mechanistic
COMPOUND 8L [PMID: 36053746] ↓ inhibits Mechanistic
COMPOUND 13AC [PMID: 33256400] ↓ inhibits Mechanistic
FEDRATINIB ↓ inhibits Mechanistic 100.0 nM (IC50)
FILGOTINIB MALEATE ↓ inhibits Mechanistic
PF-956980 ↓ inhibits Mechanistic
SDC-1801 ↓ inhibits Mechanistic
ROPSACITINIB ↓ inhibits Mechanistic
COMPOUND 18E [PMID: 31670517] ↓ inhibits Mechanistic
UPADACITINIB HEMIHYDRATE ↓ inhibits Mechanistic
BLOVACITINIB ↓ inhibits Mechanistic
DEURUXOLITINIB ↓ inhibits Mechanistic
RUXOLITINIB PHOSPHATE ↓ inhibits Mechanistic
SOLCITINIB ↓ inhibits Mechanistic
CEE321 ↓ inhibits Mechanistic
NIK INHIBITOR 12F ↓ inhibits Mechanistic

Showing top 40 of 233 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CEP-33779 ↓ inhibits Mechanistic
ITACNOSERTIB ↓ inhibits Mechanistic
FILGOTINIB ↓ inhibits Mechanistic
CEE321 ↓ inhibits Mechanistic
MOMELOTINIB ↓ inhibits Mechanistic
GILTERITINIB ? unclear Mechanistic
PEMBROLIZUMAB ? unclear Mechanistic
NEZULCITINIB ↓ inhibits Mechanistic
GANDOTINIB ↓ inhibits Mechanistic
PACRITINIB ↓ inhibits Mechanistic
CEP-11981 ? unclear Mechanistic
GUSACITINIB ↓ inhibits Mechanistic
ITACITINIB ↓ inhibits Mechanistic
ENTRECTINIB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic 94.0 nM (Kd)
TOFACITINIB CITRATE ↓ inhibits Mechanistic
DOVITINIB ? unclear Mechanistic 7000.0 nM (Kd)
6-AZAURIDINE ? unclear Mechanistic
BOMEDEMSTAT ? unclear Mechanistic
AT-9283 ↓ inhibits Mechanistic 1.2 nM (IC50)
UPADACITINIB ↓ inhibits Mechanistic
RUXOLITINIB ↓ inhibits Mechanistic
TOZASERTIB ? unclear Mechanistic 190.0 nM (Kd)
AZD1208 ? unclear Mechanistic
DECERNOTINIB ↓ inhibits Mechanistic
RG-1530 ↓ inhibits Mechanistic
HG-10-102-01 ↓ inhibits Mechanistic
ROVADICITINIB ↓ inhibits Mechanistic
JAK3 INHIBITOR II ↓ inhibits Mechanistic
IZENCITINIB ↓ inhibits Mechanistic
EMZELTRECTINIB ↓ inhibits Mechanistic
FEDRATINIB ↓ inhibits Mechanistic
LESTAURTINIB ↓ inhibits Mechanistic
OLAPARIB ? unclear Mechanistic
FEDRATINIB HYDROCHLORIDE ↓ inhibits Mechanistic
JNJ-7706621 ↓ inhibits Mechanistic 220.0 nM (Kd)
TOFACITINIB ↓ inhibits Mechanistic 11.0 nM (IC50)
DELGOCITINIB ↓ inhibits Mechanistic
BINIMETINIB ? unclear Mechanistic
BIIB068 ↓ inhibits Mechanistic

Showing top 40 of 307 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AFAMELANOTIDE ↑ activates Mechanistic 0.5 nM (Ki)
[125I]NDP-MSH ↑ activates Mechanistic
HS024 ↓ inhibits Mechanistic
BREMELANOTIDE ↑ activates Mechanistic
CORTICOTROPIN ↑ activates Mechanistic
MS05 ↑ activates Mechanistic
MT-II ↑ activates Mechanistic
&ALPHA;-MSH ↑ activates Mechanistic
ASIP [90-132 (L89Y)] ↓ inhibits Mechanistic
ISOFLURANE ? unclear Mechanistic
DERSIMELAGON ↑ activates Mechanistic
SETMELANOTIDE ↑ activates Mechanistic
SHU9119 ↑ activates Mechanistic
HS014 ↑ activates Mechanistic
DESIPRAMINE ? unclear Mechanistic
AFAMELANOTIDE ACETATE ↑ activates Mechanistic
MODIMELANOTIDE ↑ activates Mechanistic
CHEMBL437822 ↑ activates Mechanistic 1330.0 nM (EC50)
CHEMBL24892 ↑ activates Mechanistic 0.4 nM (EC50)
CHEMBL412174 ↑ activates Mechanistic 140.0 nM (EC50)
CHEMBL264337 ↑ activates Mechanistic 480.0 nM (EC50)
CHEMBL439361 ↑ activates Mechanistic 1275.0 nM (EC50)
CHEMBL2371902 ↑ activates Mechanistic 5.0 nM (EC50)
CHEMBL3037885 ↑ activates Mechanistic 0.3 nM (EC50)
CHEMBL410148 ↑ activates Mechanistic 12.0 nM (EC50)
CHEMBL2371880 ↑ activates Mechanistic 735.0 nM (EC50)
CHEMBL415341 ↓ inhibits Mechanistic 5815.0 nM (IC50)
CHEMBL2371903 ↑ activates Mechanistic 3.0 nM (EC50)
CHEMBL2371913 ↑ activates Mechanistic 900.0 nM (EC50)
CHEMBL386871 ↑ activates Mechanistic 480.0 nM (EC50)
CHEMBL384036 ↓ inhibits Mechanistic 14790.0 nM (IC50)
MELATONAN ↑ activates Mechanistic 0.6 nM (EC50)
CHEMBL407754 ↑ activates Mechanistic 370.0 nM (EC50)
CHEMBL2371887 ↑ activates Mechanistic 420.0 nM (EC50)
CHEMBL407825 ↓ inhibits Mechanistic 47.5 nM (Ki)
CHEMBL316259 ↓ inhibits Mechanistic 30.0 nM (Ki)
CHEMBL88630 ↓ inhibits Mechanistic 86.5 nM (Ki)
CHEMBL312998 ↓ inhibits Mechanistic 11.5 nM (Ki)
CHEMBL316038 ↓ inhibits Mechanistic 125.0 nM (Ki)
CHEMBL419307 ↓ inhibits Mechanistic 6.0 nM (Ki)

Showing top 40 of 139 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
JAK3 INHIBITOR 34 ↓ inhibits Mechanistic
SDC-1801 ↓ inhibits Mechanistic
TOFACITINIB ↓ inhibits Mechanistic 250.0 nM (Kd)
GOLIDOCITINIB ↓ inhibits Mechanistic
TYK2 INHIBITOR 18 [WO2023227946] ~ modulates Mechanistic
GDC-0214 ↓ inhibits Mechanistic
TAMATINIB ? unclear Mechanistic
JAK INHIBITOR 20A ↓ inhibits Mechanistic
NVP-TAE684 ? unclear Mechanistic
PEFICITINIB ↓ inhibits Mechanistic
TYD-68 ? unclear Mechanistic
BREPOCITINIB ↓ inhibits Mechanistic
LORPUCITINIB ↓ inhibits Mechanistic
COMPOUND 25AP [PMID: 37796543] ↓ inhibits Mechanistic
TOZASERTIB ? unclear Mechanistic 510.0 nM (Kd)
FILGOTINIB MALEATE ↓ inhibits Mechanistic
DEURUXOLITINIB PHOSPHATE ↓ inhibits Mechanistic
MOMELOTINIB ↓ inhibits Mechanistic
COMPOUND 13 [PMID: 34333981] ↓ inhibits Mechanistic
DEUCRAVACITINIB ~ modulates Mechanistic
CADEFRECITINIB ↓ inhibits Mechanistic
RUXOLITINIB ↓ inhibits Mechanistic 19.0 nM (IC50)
JNJ-7706621 ? unclear Mechanistic 32.0 nM (Kd)
BMS-986202 ↓ inhibits Mechanistic
FILGOTINIB ↓ inhibits Mechanistic
COMPOUND 30 [PMID: 37057760] ↓ inhibits Mechanistic
SJ988497 ? unclear Mechanistic
RECOMBINANT INTERLEUKIN-2 ? unclear Mechanistic
CERDULATINIB ↓ inhibits Mechanistic
EDODEKIN ALFA ? unclear Mechanistic
RG-1530 ? unclear Mechanistic
FEDRATINIB ↓ inhibits Mechanistic 150.0 nM (IC50)
UPADACITINIB ↓ inhibits Mechanistic
SAR-20347 ↓ inhibits Mechanistic
ZOTIRACICLIB ↓ inhibits Mechanistic
G&OUML; 6976 ? unclear Mechanistic
COMPOUND 13AC [PMID: 33256400] ↓ inhibits Mechanistic
TYK2 INHIBITOR 14L ↓ inhibits Mechanistic
OCLACITINIB ↓ inhibits Mechanistic
ILORASERTIB ? unclear Mechanistic

Showing top 40 of 223 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ARBUTIN ↓ inhibits Mechanistic 30260.0 nM (IC50)
NEORAUFLAVANE ↓ inhibits Mechanistic
MEQUINOL ↓ inhibits Mechanistic
LUTEOLIN ? unclear Mechanistic 60000.0 nM (IC50)
HYDROQUINONE ? unclear Mechanistic 15000.0 nM (IC50)
N-PHENYLTHIOUREA ? unclear Mechanistic
KOJIC ACID ? unclear Mechanistic 22940.0 nM (IC50)
CHRYSIN ? unclear Mechanistic
MONOBENZONE ↓ inhibits Mechanistic
IMMUNOTHERAPY REGIMEN MKC-1106-MT ? unclear Mechanistic
MELANOMA VACCINE ? unclear Mechanistic
ALPHA-THUJAPLICIN ? unclear Mechanistic
CHEMBL430491 ↓ inhibits Mechanistic 780.0 nM (IC50)
CHEMBL98924 ↓ inhibits Mechanistic 390.0 nM (IC50)
CHEMBL98925 ↓ inhibits Mechanistic 330.0 nM (IC50)
CHEMBL321140 ↓ inhibits Mechanistic 4480.0 nM (IC50)
CHEMBL432017 ↓ inhibits Mechanistic 2180.0 nM (IC50)
CHEMBL317947 ↓ inhibits Mechanistic 2130.0 nM (IC50)
CHEMBL317040 ↓ inhibits Mechanistic 240.0 nM (IC50)
CHEMBL95890 ↓ inhibits Mechanistic 6170.0 nM (IC50)
CHEMBL25249 ↓ inhibits Mechanistic 16660.0 nM (IC50)
CHEMBL25640 ↓ inhibits Mechanistic 3030.0 nM (IC50)
CHEMBL26443 ↓ inhibits Mechanistic 23210.0 nM (IC50)
CHEMBL1793857 ↓ inhibits Mechanistic 15350.0 nM (IC50)
CHEMBL24152 ↓ inhibits Mechanistic 60.0 nM (IC50)
CHEMBL1794031 ↓ inhibits Mechanistic 700.0 nM (IC50)
CHEMBL24579 ↓ inhibits Mechanistic 14510.0 nM (IC50)
CHEMBL24765 ↓ inhibits Mechanistic 8000.0 nM (IC50)
CHEMBL25350 ↓ inhibits Mechanistic 2390.0 nM (IC50)
CHEMBL24151 ↓ inhibits Mechanistic 2000.0 nM (IC50)
CHEMBL350966 ↓ inhibits Mechanistic 30000.0 nM (IC50)
CUMINALDEHYDE ↓ inhibits Mechanistic 50000.0 nM (IC50)
CHAMAECIN ↓ inhibits Mechanistic 2300.0 nM (IC50)
BRYOAMARIDE ↓ inhibits Mechanistic 85010.0 nM (IC50)
CYCLOORBICOSIDE G ↓ inhibits Mechanistic 54640.0 nM (IC50)
ASKENDOSIDE B ↓ inhibits Mechanistic 13950.0 nM (IC50)
ASKENDOSIDE D ↓ inhibits Mechanistic 48920.0 nM (IC50)
CYCLOSIEVERSIOSIDE ↓ inhibits Mechanistic 92250.0 nM (IC50)
CHEMBL201626 ↓ inhibits Mechanistic 38000.0 nM (IC50)
CHEMBL199975 ↓ inhibits Mechanistic 31700.0 nM (IC50)

Showing top 40 of 162 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Vitiligo: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07889492 Phase: 2 Started: 2026-09

The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe non-segmental vitiligo.. Vitiligo is a chronic autoimmune skin disorder characteri...

NCT06905873 Phase: 1 Started: 2025-03-25

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

NCT06072183 Phase: 3 Started: 2023-11-08

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sid...

NCT07431177 Phase: 2 Started: 2026-03-09

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

NCT06625177 Phase: 1 Started: 2024-11-11

The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.

NCT06804811 Phase: 3 Started: 2025-11-13

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

NCT07532330 Phase: N/A Started: 2025-08-01

The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations. The main questions it aims to answer are: Which combination (UVB + tacrolimus or UV...

NCT07533019 Phase: 2 Started: 2026-04-14

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to inv...

NCT07108283 Phase: 2 Started: 2025-11-03

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less...

NCT06163326 Phase: 3 Started: 2024-01-19

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-se...

NCT07820098 Phase: 2 Started: 2026-04-08

This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an acti...

NCT06548360 Phase: 3 Started: 2025-01-24

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

NCT07353801 Phase: 4 Started: 2026-02-28

The goal of this clinical trial is to learn if oral mini pulse (OMP) dexamethasone works to treat active vitiligo in children and also learn about the safety of this drug within this age group the main questions it aims to answer are does OMP halt activity in active vitiligo and what medical problem...

NCT06113445 Phase: 3 Started: 2023-11-29

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

NCT07682506 Phase: 3 Started: 2026-08-04

This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.


Agents Found By Disease-Level Search

Searched directly from “Vitiligo” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

45 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.

Ruxolitinib creamNOT in gene-target list

· 6 trials · source: ClinicalTrials.gov
NCT03099304 NCT04057573 NCT04052425

PF-06651600NOT in gene-target list

· 5 trials · source: ClinicalTrials.gov
NCT03715829 NCT03715829 NCT03715829

NB-UVB phototherapyNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT03123016 NCT05247489 NCT05298033

Ritlecitinib

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT06163326 NCT06072183 NCT06072183

Upadacitinib

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06118411 NCT04927975

narrow-band UVB phototherapyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03715829 NCT07532330

Topical tacrolimus 0.1% ointmentNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03047733 NCT07532330

SHR0302Base gelNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06790862 NCT07251595

ApremilastNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03123016

derma penNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05467839

Ruxolitinib 1.5% Cream BIDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07153666

Needling + NBUVBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06991972

Deucravacitinib

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06327321

PF06700841NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03715829

LITFULONOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07152626

LITFULO and UVBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07152626

VITICELLNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02156427

Ritlecitinib 100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06163326

Coenzyme Q10NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07677826

Vitamin CNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07677826

AzathioprineNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07044141

Tofacitinib

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07044141

Ginkgo bilobaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00907062

Ruxolitinib Topical CreamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07725432

Grafting with epidermal cellsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01629979

UVB treatmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01629979

Gingival depigmentationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06075641

oral mini pulseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05706636

Topical creamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05706636

targeted phototherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05706636

Autologous Nanofat InjectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07763262

dibotatug (DR-01)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06602232

1.5% Ruxolitinib Phosphate Cream (Opzelura)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07673640

Corticosteroid TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07673640

Ruxolitinib TopicalNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05872477

MethotrexateNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04237103

EtanerceptNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00134368

ReCellNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02458417

diphenylcyclopropenone (DPCP)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04775979

Drug: CGB-600 gel, experimental drugNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07357870

Dexamethasone (0.1 mg/kg)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07353801

Ruxolitinib 1.5% creamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05247489

FB102NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06905873

MH004 1.0% OintmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07682506

Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinetNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03270241

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.